Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03629899Not ApplicableWithdrawn

RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

Role: collaborator

NCT02588430Withdrawn

PMCF Study for Partial Vision Restoration Using the Subretinal Implant RETINA IMPLANT Alpha AMS

Role: lead

NCT03561922Not ApplicableTerminated

Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS

Role: lead

NCT01024803Not ApplicableCompleted

Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

Role: lead

NCT01497379Not ApplicableCompleted

Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

Role: lead

NCT00515814Not ApplicableCompleted

Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors

Role: lead

All 6 trials loaded